The most common of the documented sermorelin side effects is a local injection-site reaction — pain, swelling or redness — reported in roughly one patient in six. Every other treatment-related adverse event in the clinical record occurred in under 1% of patients. Of 350 people exposed to sermorelin in those trials, three stopped treatment because of injection reactions.
Why sermorelin's side effects are mild
Sermorelin is a fragment of growth hormone-releasing hormone — the first 29 amino acids, the part that carries the activity. It does not supply growth hormone. It signals your pituitary to release its own.
That distinction shapes the whole safety profile. Because the pituitary is still the one deciding, the body's feedback loops stay intact: somatostatin still brakes release, and growth hormone still arrives in pulses rather than as a flat elevated level. The failure mode of supplying growth hormone directly — pushing levels past what the body would ever produce, and suppressing the axis that normally regulates it — is largely structural rather than dose-dependent, and sermorelin sidesteps it by working upstream. We cover the comparison in sermorelin versus HGH.
This is also why sermorelin's ceiling is lower. A pituitary that cannot respond will not be made to.
The documented sermorelin side effects
From the prescribing information for the sermorelin product studied in growth hormone deficiency:
| Effect | Frequency |
|---|---|
| Injection-site reaction (pain, swelling, redness) | ~1 in 6 patients |
| Headache | <1% |
| Flushing | <1% |
| Difficulty swallowing | <1% |
| Dizziness | <1% |
| Hyperactivity | <1% |
| Somnolence | <1% |
| Urticaria (hives) | <1% |
Transient facial flushing and injection-site pain were the most commonly reported events overall. Intravenous single doses and repeated once-daily subcutaneous doses were well tolerated.
One item deserves separate attention: hypothyroidism was observed in 6.5% of patients during therapy, which is why thyroid function is monitored on sermorelin rather than assumed. Untreated hypothyroidism also blunts the growth hormone response, so this is a matter of whether the treatment works as much as whether it is safe.
The limitation nobody mentions
The safety data above comes overwhelmingly from studies in children with idiopathic growth hormone deficiency, where sermorelin was used diagnostically and therapeutically (Prakash & Goa, BioDrugs 1999).
Most people asking about sermorelin today are adults considering it for sleep, body composition or recovery. That is a different population, a different indication and often a different dosing pattern. The trial numbers remain the best evidence available, and they should be read as informative rather than directly transferable.
One piece of adult evidence is worth noting. A six-week study of single nightly GHRH (1-29) injections in healthy elderly men found no significant adverse effects, and the growth-hormone-releasing response was sustained rather than fading — the axis kept responding instead of desensitising (Vittone et al., Metabolism 1997). The same study found nightly dosing less effective than multiple daily doses at producing downstream effects, which is a useful reminder that tolerability and benefit are separate questions.
What people commonly report
Beyond the documented list, the effects users describe most are local and transient: redness or itching at the injection site, occasional flushing shortly after a dose, and vivid dreams or altered sleep, which is unsurprising given that growth hormone release is normally tied to deep sleep and sermorelin is typically taken at night.
Some report water retention, joint aches or tingling in the hands. These are recognised effects of raised growth hormone activity generally, tend to be dose-related, and typically settle or resolve with a dose adjustment. They are worth reporting to your prescriber rather than tolerating indefinitely.
Who should not take sermorelin
Sermorelin is contraindicated in anyone with known sensitivity to it or to the excipients in the formulation. It should not be used by people whose growth hormone deficiency stems from an intracranial lesion, and it is not appropriate during pregnancy or breastfeeding.
An active cancer diagnosis calls for direct discussion: growth hormone and IGF-1 are growth-signalling pathways, and raising them is not a decision to make around an untreated malignancy. Untreated hypothyroidism should be corrected first, since it suppresses the response. Anyone on other medications should have them reviewed.
Where a prescriber fits
Through Promise, sermorelin is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality.
A licensed provider in Promise's prescriber network reviews every request against your history — thyroid status, cancer history, other prescriptions — and prescribes only when sermorelin is appropriate for you. They can and do decline. Not everyone qualifies, and the intake questionnaire exists to establish that before anything is dispensed.
For what sermorelin is used for and what to expect from it, see sermorelin benefits, or the hormone and organ health hub for the wider category.
When to contact your provider
Call about any allergic reaction — hives, swelling, difficulty breathing or swallowing. Also call for persistent headache, vision changes, ongoing joint pain or swelling, numbness or tingling in the hands, or an injection-site reaction that worsens rather than settles over a few days.
Mild redness at the injection site that fades within a day is the expected experience. Anything escalating is not.